Recent Updates
Recently added Catalysts
AEMD

Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation

Key Takeaway: SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the

Full Press Release Details

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced that an audio rebroadcast of the presentation by its Chairman and CEO, James A. Joyce, at the Biotech Showcase™ 2012, on January 9, 2012, is now be available at:
In addition, the slide presentation is available at:
Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives during the course of the industry's largest annual healthcare investor conference.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Chief Financial Officer
Director, Communications
SOURCE Aethlon Medical, Inc.

21 %

more press release views with
Last updated: Jan 9, 2012